Association of the serum level of apolipoprotein E with coronary artery disease and carotid artery atherosclerosis in Kyrgyz men with dyslipidemia


Cite item

Full Text

Abstract

Aim: to study an association of the serum level of apolipoprotein E (apo-E) with risk factors for coronary heart disease (CHD), blood lipids and that with CHD and carotid artery (CA) atherosclerotic lesion in Kyrgyz men with dyslipidemia.
Subjects and methods. One hundred and three Kyrgyz men, including 48 with CHD and 55 without this disease, were examined. A clinical examination was performed and blood lipid composition and serum glucose and apo-E levels were determined. The diagnosis of CHD was established in accordance with the conventional criteria. Whether atherosclerosis was present was determined by ultrasound duplex scanning.
Results. Low serum apo-E concentrations were associated with the presence of obesity, the higher blood levels of glucose and triglycerides. There was no correlation with other lipid metabolic parameters and the presence of CHD. A nonlinear relationship was noted between serum apo-E levels and CA atherosclerotic lesion, which was more frequently observed in patients with the apo-E level in the lower and upper quartiles.
Conclusion. Low serum apo-E content is a poor factor and associated with obesity, hypertriglyceridemia, elevated serum glucose levels, and the development of CA atherosclerosis.

References

  1. Boisvert W. A., Curtiss L. K. Elimination of macrophage specific apolipoprotein E reduces diet-induced atherosclerosis in C57Bl/6 J male mice. J. Lipid Res. 1999; 40: 806-813.
  2. Van Eck M., Herijgers N., Vidgeon-Hart M. et al. Accelerated atherosclerosis in C57Bl/6 mice transplanted with ApoE-deficient bone marrow. Atherosclerosis 2000; 150: 71-80.
  3. Gough P. J., Raines E. W. Gene therapy of apolipoprotein E-deficient mice using a novel macrophage-specific retroviral vector. Blood 2003; 101: 485-491.
  4. Thorngate F. E., Rudel L. L., Walzem R. L., Williams D. L. Low levels of extrahepatic nonmacrophage apoE inhibit atherosclerosis without correcting hypercholesterolemia in apoE-deficient mice. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 1939-1945.
  5. Schaefer E. J., Gregg R. E., Ghiselli G. et al. Familial apolipoprotein E deficiency. J. Clin. Invest. 1986; 78: 1206-1219.
  6. Bellosta S., Mahley R. W., Sanan D. A. et al. Macrophage-specific expression of human apolipoprotein E reduces atherosclerosis in hypercholesterolemic apolipoprotein E-null mice. J. Clin. Invest. 1995; 96: 2170-2179.
  7. Riddell D. R., Graham A., Owen J. S. Apolipoprotein E inhibits platelet aggregation through the L-arginine: nitric oxide pathway. Implications for vascular disease. J. Biol. Chem. 1997; 272: 89-95.
  8. Sacre S. M., Stannard A. K., Owen J. S. Apolipoprotein E isoforms differentially induce nitric oxide production in endothelial cells. FEBS Lett. 2003; 540: 181-187.
  9. Kelly M. E., Clay M. A., Mistry M. J. et al. Apolipoprotein E inhibition of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity. Cell. Immunol. 1994; 159: 124-139.
  10. Palinski W., Ord V. A., Plump A. S. et al. ApoE-deficient mice are a model of lipoprotein oxydation in atherogenesis: demonstration of oxydationspecific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 1994; 14: 605-616.
  11. Greenow K., Pearce N. J., Ramji D. P. The key role of apolipoprotein E in atherosclerosis. J. Mol. Med. 2005; 83: 329-342.
  12. Fridewald W. T., Levy R. I., Fredrickson D. S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 1972; 18: 499-502.
  13. Alberty K. G., Zimmet P. Z., Shaw J. The metabolic syndrome a new worldwide definition. Lancet 2005; 366: 1059-1062.
  14. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379-1387.
  15. Бутрова С. А. Метаболический синдром: патогенез, клиника, диагностика, подходы к лечению. Рус. мед. журн. 2001; 9(2): 56-61.
  16. Mooijaart S. P., Berbee J. F. P., van Heemst D. et al. ApoE plasma levels and risk of cardiovascular mortality in old age. J. PLoS Med. 2006; 3: 874-882.
  17. Mooijaart S. P., Vliet P. V., Heemst D. V. et al. Plasma levels of apolipoprotein E and cognitive function in old age. Ann. N. Y. Acad. Sci. 2007; 1100: 140-147.
  18. Стакишайтис Д. В., Янчаускине С. М., Ивашкявичине Л. И. и др. Атерогенез и содержание аполипопротеина Е в сыворотке крови. Кардиология 1992; 12: 30-33.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2010 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies